Maternal Motivation to Take Preventive Therapy in Antepartum and Postpartum Among HIV-Positive Pregnant Women in South Africa: A Choice Experiment

HIV-positive pregnant women who are initiated on lifelong antiretroviral therapy (ART) and isoniazid preventive therapy (IPT) have lower adherence rates after delivery. We quantified maternal motivation to take preventive therapy before and after delivery among pregnant women newly diagnosed with HIV. We enrolled pregnant women (18years) with a recent HIV diagnosis (<6months) at 14 public primary health clinics in Matlosana, South Africa and followed them in the postpartum period. Participants received eight choice tasks comparing two mutually exclusive sub-sets of seven possible benefits related to preventive therapy identified through literature reviews and key informant interviews. Data was analyzed using conditional logit regression in the antepartum versus postpartum periods. Coefficients are reported with 95% confidence intervals (CI). Sixty-five women completed surveys both at enrollment and in the postpartum period. All women were already on ART, while 21 (32%) were receiving IPT at enrollment. The mean CD4 count was 436 (+/- 246) cells/mm(3). In the antepartum period, preventing HIV transmission to partners was the most important benefit (coefficients (beta)=0.87, 95% CI 0.64, 1.11), followed by keeping healthy for family (beta=0.75, 95% CI 0.52, 0.97). Such prioritization significantly decreased in the postpartum period (p<0.001). Compared to other motivators, keeping a high CD4 count was least prioritized in the antepartum period (beta=0.19, 95% CI -0.04, 0.43) but was most prioritized in the postpartum period (beta=0.39, 95% CI 0.21, 0.57). These results highlight that messages on family might be particularly salient in the antepartum period, and keeping CD4 count high in the postpartum period. Understanding maternal motivation may help to design targeted health promotion messages to HIV-positive women around the time of delivery.